KALAMAZOO, Mich.--(BUSINESS WIRE)--Aug 6, 2024--
Stryker (NYSE: SYK), a global leader in medical technologies, announced the launch of its Pangea Plating System, which received FDA clearance in late 2023. Pangea offers a comprehensive and versatile portfolio, providing variable-angle plating for a variety of patient populations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240806005748/en/
“The launch of the Pangea Plating System marks a significant milestone for Stryker, our customers and the patients they serve,” said Eric Tamweber, vice president and general manager, Stryker’s Trauma business. “With the addition of Pangea, Stryker is the go-to partner for everything trauma – nails, plates, external fixation devices, and more, backed by our dedicated team and exceptional service.”
Among the 26 pioneering surgeons leading the way with Pangea are:
The Pangea Plating System is indicated for the internal fixation and stabilization of bone fractures, osteotomies and arthrodesis in normal and osteopenic bone. Offering an evidence-based design for implant fit, the system was designed to enhance plate fit and screw placement while elevating the plating market through anatomically contoured implants in patient populations with a wide variety of fracture patterns. The intuitive and streamlined instrumentation and implant trays include 20 anatomic plates and 13 utility plates all accessible in one platform.
Stryker will host The Pangea Experience for its customers on Aug. 9 and 10, 2024, at the MGM Grand in Las Vegas. The event will showcase Stryker’s latest trauma technology, offering operational insights and strategy discussions. Attendees will have the opportunity to share opinions, discover advanced solutions and gain strategies to stay at the forefront of trauma innovation.
About Stryker
Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at www.stryker.com.
This document is intended solely for healthcare professionals. A surgeon must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Stryker does not dispense medical advice and recommends that surgeons be trained in the use of any particular product before using it in surgery.
The information presented is intended to demonstrate the breadth of Stryker’s product offerings. A surgeon must always refer to the package insert, product label and/or instructions for use before using any of Stryker’s products. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your sales representative if you have questions about the availability of products in your area.
Stryker Corporation or its affiliates own, use, or have applied for the following trademarks or service marks: Stryker. All other trademarks are trademarks of their respective owners or holders.
Content ID: PGA-AR-2_35828
Stryker’s Pangea Plating System is indicated for the internal fixation and stabilization of bone fractures, osteotomies and arthrodesis in normal and osteopenic bone. (Photo: Business Wire)
